Allogene Therapeutics
Glenn Davis is an experienced professional in the biotechnology and pharmaceuticals sector, currently serving as Vice President of Portfolio and Program Management at Allogene Therapeutics since July 2024. Previously, Glenn held key leadership roles in program management at Replay, Arrowhead Pharmaceuticals, Kite Pharma, Takeda, and Amgen, contributing to projects within cell therapy, gastrointestinal therapeutics, and digital health initiatives. Glenn's career began with research internships at the Mayo Clinic and the University of Virginia. Educational qualifications include an MBA in International Business, Management, and Organizational Behavior, as well as a BS in Biology with an emphasis on Molecular Biology and Biochemistry, both from California Lutheran University.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.